The mutation of IDH1 in glioma is associated with a hyper-methylation phenotype, which activates HIF and inactivates α-ketoglutarate in glioma (Fu et al., 2012; Lu et al., 2012; Turcan et al., 2012). Here, IDH1 is linked to central nervous system cancer.